Beyond Air
XAIR | NASDAQ
$2.02
-$0.11 (-5.16%)
At close: Nov 16, 2026, 4:00 PM ET
$1.92
-$0.10 (-4.95%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Beyond Air Company Profile
Company profile explainedCompany Profile
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Key Executives
| Name | Position |
|---|---|
| Amir Avniel | Chief Executive Officer of NeuroNOS |
| Robert Scott Goodman | CEO & Director |
| Daniel J. Moorhead | Chief Financial Officer |
| Michael A. Gaul | Chief Operating Officer |
| Adam Newman | Corporate Secretary |
| Andrew R. Colin | Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board |
| Denton Drewell | Principal Accounting Officer & Controller |
| John Jett | Head of Research & Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | DEFA14A | Filing |
| Oct 30, 2026 | DEF 14A | Filing |
| Oct 21, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 20, 2026 | PRE 14A | Filing |
| Oct 14, 2026 | 4 | Filing |
| Oct 08, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 3 | Filing |
| Oct 02, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 24, 2026 | 8-K | Current Report |
Beyond Air
| Country | United States |
| IPO Date | Jun 12, 2018 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Robert Goodman |
Contact Details
900 Stewart Avenue Garden City,
New York 11530 United States
Stock Details
| Ticker Symbol | XAIR |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001641631 |
| CUSIP Number | 08862L301 |
| ISIN Number | US08862L3015 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove XAIR